← Back to Search

Biguanide

Metformin for Polycystic Ovary Syndrome

Phase < 1
Recruiting
Led By Christine Burt Solorzano, MD
Research Sponsored by University of Virginia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Overweight females (>85th BMI%)
Be younger than 65 years old
Must not have
Morning cortisol < 3 µg/dL or history of Cushing syndrome or adrenal insufficiency
Previous diagnosis of diabetes, fasting glucose ≥126 mg/dL, or a hemoglobin A1c ≥6.5%
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks after metformin administration
Awards & highlights

Summary

This trial will test whether the drug metformin can lower androgen levels in overweight pubertal girls with androgen excess.

Who is the study for?
This trial is for overweight pubertal girls aged 7-18 with excess male hormones, specifically those who are in the early to late stages of puberty and have higher than normal free testosterone levels. Participants must not be pregnant, lactating, diabetic, or have certain hormonal disorders.Check my eligibility
What is being tested?
The study tests if metformin can reduce androgen overproduction in these girls. It involves a 12-week treatment period where insulin sensitivity is expected to improve and subsequently lower androgen levels after specific hormone stimulation tests.See study design
What are the potential side effects?
While not explicitly listed here, common side effects of metformin include stomach upset or discomfort, diarrhea, nausea or vomiting; however individual experiences may vary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a female and my BMI is above the 85th percentile.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My morning cortisol is low or I have had Cushing syndrome or adrenal issues.
Select...
I have diabetes or my blood sugar or A1c levels are high.
Select...
My BMI is below the 5th percentile for my age.
Select...
I have a history of congenital adrenal hyperplasia or my 17-hydroxyprogesterone levels are above 300 ng/dL.
Select...
My DHEAS levels are higher than normal for my age.
Select...
My thyroid hormone levels are not normal for my age.
Select...
I am either younger than 7 or older than 18 years old.
Select...
I have a serious heart or lung condition.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks after metformin administration
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks after metformin administration for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in free testosterone or 17-hydroxyprogesterone levels after ACTH and rhCG administration respectively, before and after metformin administration for 12 weeks
Secondary outcome measures
Changes in adrenal and ovarian steroid precursors after ACTH and rhCG; body composition via air displacement plethysmography, BMI, and glucose tolerance testing results; baseline and after 12 weeks of metformin administration

Side effects data

From 2015 Phase 4 trial • 156 Patients • NCT02002221
13%
Nasopharyngitis
10%
Hyperhidrosis
9%
Hunger
9%
Tremor
8%
Asthenia
6%
Hypoglycaemia
1%
Squamous cell carcinoma of the tongue
1%
Femoral neck fracture
100%
80%
60%
40%
20%
0%
Study treatment Arm
Vildagliptin (LAF237)
Placebo

Trial Design

1Treatment groups
Experimental Treatment
Group I: metforminExperimental Treatment1 Intervention
12 weeks metformin, with pre- and post- dexamethasone and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Metformin
FDA approved

Find a Location

Who is running the clinical trial?

University of VirginiaLead Sponsor
761 Previous Clinical Trials
1,256,018 Total Patients Enrolled
17 Trials studying Obesity
2,464 Patients Enrolled for Obesity
Christine Burt Solorzano, MDPrincipal Investigator - University of Virginia
UVA Child Development & Rehabilitation Center, University of Virginia Medical Center
University Of Virginia School Of Medicine (Medical School)
Children'S Hosp Of L A (Residency)
7 Previous Clinical Trials
275 Total Patients Enrolled
4 Trials studying Obesity
184 Patients Enrolled for Obesity

Media Library

Metformin (Biguanide) Clinical Trial Eligibility Overview. Trial Name: NCT01422746 — Phase < 1
Obesity Research Study Groups: metformin
Obesity Clinical Trial 2023: Metformin Highlights & Side Effects. Trial Name: NCT01422746 — Phase < 1
Metformin (Biguanide) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01422746 — Phase < 1
~1 spots leftby Dec 2024